Evidence map›Paper›PMID 35808806›Full record

ArticleClinical and translational medicine2022

Single-cell RNA sequencing reveals localized tumour ablation and intratumoural immunostimulant delivery potentiate T cell mediated tumour killing.

Ashley R Hoover, Kaili Liu, Christa I DeVette, Jason R Krawic, Alexandra D Medcalf, Connor L West, Tomas Hode, Samuel S K Lam, Alana L Welm, Xiao-Hong Sun and 2 more

Open access · goldAbstract read
In one paragraph

Article in Clinical and translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Exploring the role of CD8FEBS open bio · 2024
    Article
  9. Immune modulations of the tumor microenvironment in response to phototherapy.Journal of innovative optical health sciences · 2023
    Article
  10. Review
  11. Localized ablative immunotherapy drives de novo CD8Journal for immunotherapy of cancer · 2022
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Ashley R HooverStephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma, USA.ORCID 0000-0002-3555-1510
Kaili LiuStephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma, USA.
Christa I DeVetteDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Jason R KrawicDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.ORCID 0000-0003-0103-0212
Alexandra D MedcalfArthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
Connor L WestStephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma, USA.
Tomas HodeImmunophotonics Inc., St. Louis, Missouri, USA.
Samuel S K LamImmunophotonics Inc., St. Louis, Missouri, USA.
Alana L WelmHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
Xiao-Hong SunArthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
William H HildebrandDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Wei R ChenStephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma, USA.
Oklahoma Medical Research Foundation · USUniversity of Oklahoma Health Sciences Center · USNeoPhotonics (United States) · USUniversity of Oklahoma · USUniversity of Utah · USZero to Three · US

Funding

Potentiating a systemic antitumor response by interstitial localized ablative immunotherapy to synergize with immune checkpoint therapy for metastatic pancreatic tumorsR01CA269897 · NCI · UNIVERSITY OF OKLAHOMA · PI Wei R. Chen, MIN LI · 2022 to 2026
$2.5M
Mechanistic study on synergistic photo-immunological effects of laser immunotherapy for metastatic cancersR01CA205348 · NCI · UNIVERSITY OF OKLAHOMA · PI CHEN, WEI R. · 2017 to 2021
$1.5M
NCI NIH HHS R01 CA205348NCI NIH HHS R01 CA269897
6 · The paper itself

Abstract

backgroundMetastatic breast cancer poses great challenge in cancer treatment. N-dihydrogalactochitosan (GC) is a novel immunoadjuvant that stimulates systemic immune responses when administered intratumourally following local tumour ablation. A combination of photothermal therapy (PTT) and GC, referred to as localized ablative immunotherapy (LAIT), extended animal survival and generates an activated B cell phenotype in MMTV-PyMT mouse mammary tumour microenvironment (TME). However, how T cell populations respond to LAIT remains to be elucidated.

methodsUsing depletion antibodies, we studied the contributions of CD8

resultsLoss of CD8

conclusionsOverall, our results reveal that LAIT prompts immunological remodelling of T cells by inducing broad proinflammatory responses and inhibiting suppressive signalling to drive antitumour immunity.

Indexed as

CD8-Positive T-LymphocytesNeoplasmsAcetylglucosamineAdjuvants, ImmunologicAnimalsMiceSequence Analysis, RNATumor MicroenvironmentAcetylglucosamineAdjuvants, ImmunologicN-dihydrogalactochitosanantitumour immune responselocalized ablative immunotherapy (LAIT)mouse mammary tumour virus-polyoma middle T (MMTV-PyMT)N-dihydrogalactochitosan (GC)photothermal therapy (PTT)single-cell RNA sequencing (scRNAseq)tumour-infiltrating T cells

Identifiers

PMID35808806
PMCPMC9270578
OpenAlexW4284989996

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.